首页 > 最新文献

Hipertension y Riesgo Vascular最新文献

英文 中文
Importance of blood pressure monitoring in the acute phase of stroke. An update 中风急性期血压监测的重要性。最新进展。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.hipert.2024.01.002

Introduction

The evaluation of blood pressure (BP) is essential in the acute phase of stroke. Although ambulatory blood pressure monitoring (ABPM) is a validated method for BP control, there are few studies assessing the usefulness of ABPM in the acute phase of stroke.

Development

A systematic review was carried out according to the PRISMA criteria in the PubMed/Medline and Scopus databases. Those articles that analysed the use of ABPM in the first days after suffering a stroke from 1992 to 2022 were selected. Those articles focused on the post-acute or sequelae phase of the stroke, with a sample size of less than 20 and those where the primary objective was different from the defined one. A total of 28 articles were included.

Conclusions

The use of ABPM in patients with recent stroke demonstrates that the normal circadian profile of BP is altered in more than two-thirds of patients and that this will be fundamentally conditioned by the haemodynamic changes that occur on autoregulation of cerebral blood flow, the type of stroke or the response to treatment. Furthermore, these changes in BP have prognostic implications and are correlated with functional status, stroke recurrence and mortality, among others. However, although they continue to be a growing area of research, new studies are needed to clarify the real role of this technique in patients with acute stroke.

简介评估血压(BP)对中风急性期至关重要。尽管非卧床血压监测(ABPM)是一种有效的血压控制方法,但很少有研究评估 ABPM 在中风急性期的作用:根据 PRISMA 标准,在 PubMed/Medline 和 Scopus 数据库中进行了系统性综述。选取了 1992 年至 2022 年间分析中风后最初几天 ABPM 使用情况的文章。这些文章侧重于中风的急性期或后遗症期,样本量少于 20 个,且主要目标与定义目标不同。共纳入 28 篇文章:对近期中风患者使用 ABPM 表明,超过三分之二的患者血压的正常昼夜节律发生了改变,而这将从根本上受制于脑血流自动调节过程中发生的血流动力学变化、中风类型或对治疗的反应。此外,血压的这些变化对预后也有影响,并与功能状态、中风复发和死亡率等相关。然而,尽管血压变化仍是一个不断扩大的研究领域,但仍需要新的研究来明确该技术在急性中风患者中的真正作用。
{"title":"Importance of blood pressure monitoring in the acute phase of stroke. An update","authors":"","doi":"10.1016/j.hipert.2024.01.002","DOIUrl":"10.1016/j.hipert.2024.01.002","url":null,"abstract":"<div><h3>Introduction</h3><p>The evaluation of blood pressure (BP) is essential in the acute phase of stroke. Although ambulatory blood pressure monitoring (ABPM) is a validated method for BP control, there are few studies assessing the usefulness of ABPM in the acute phase of stroke.</p></div><div><h3>Development</h3><p>A systematic review was carried out according to the PRISMA criteria in the PubMed/Medline and Scopus databases. Those articles that analysed the use of ABPM in the first days after suffering a stroke from 1992 to 2022 were selected. Those articles focused on the post-acute or sequelae phase of the stroke, with a sample size of less than 20 and those where the primary objective was different from the defined one. A total of 28 articles were included.</p></div><div><h3>Conclusions</h3><p>The use of ABPM in patients with recent stroke demonstrates that the normal circadian profile of BP is altered in more than two-thirds of patients and that this will be fundamentally conditioned by the haemodynamic changes that occur on autoregulation of cerebral blood flow, the type of stroke or the response to treatment. Furthermore, these changes in BP have prognostic implications and are correlated with functional status, stroke recurrence and mortality, among others. However, although they continue to be a growing area of research, new studies are needed to clarify the real role of this technique in patients with acute stroke.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic biomarkers and cardiovascular risk stratification in hypertension 高血压的代谢生物标志物和心血管风险分层。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.hipert.2024.06.003
D. Piskorz, L. Keller, L. Citta, G. Tissera, L. Mata, L. Bongarzoni

Introduction

Cardiovascular risk calculators (CRC) are not locally validated and calibrated. Surrogate biomarkers of insulin resistance had identified subjects at higher risk of type 2 diabetes and cardiovascular disease.

Aim

Establish the frequency of surrogate biomarkers of insulin resistance and their correlation with CRC in primary prevention non-diabetic hypertensive subjects.

Methods

This is an observational registry with a prospective consecutive outpatient's sample. The TyG index (TyGi) was calculated as logarithm (Ln) of (fasting triglycerides [mg/dl] × fasting plasma glucose [mg/dl]/2). Patients were stratified according to quartiles of TyGi. Pearson correlation coefficient between TyGi and other relevant variables was evaluated.

Results

Four hundred six patients were included with a mean age 55.9 ± 13 years, 231 p (56.9%) males. The mean TyGi was 8.667 ± 0.53. Patients in the highest quartiles of TyGi had significantly higher median difference between expected and actual ASCVD risk (p = 0.02), higher frequency of AHA/ACC Pooled Cohort Equation >7.5% (p < 0.005), and higher levels of metabolic biomarkers such as median triglyceridemia/HDL cholesterol ratio (TG/HDL) (p < 0.0005), glycaemia and A1C (p < 0.001 and p = 0.02, respectively). The correlation between TyGi and TG/HDL was highly significant (r = 0.7076; r2 = 0.5007; p < 0.0001), and intermediate with non-HDL cholesterol (r = 0.4553, r2 = 0.2073; p < 0.0001).

Conclusions

Non-diabetic hypertensive patients with high TyGi, a surrogate biomarker of insulin resistance, had a higher 10-year cardiovascular risk by AHA/ACC Pooled Cohort Equation. TyGi is statistically and significantly correlated with other biomarkers of insulin resistance. TyGi could be a reliable biomarker in clinical practice to stratify cardiovascular risk.

导言:心血管风险计算器(CRC)未经当地验证和校准。胰岛素抵抗的替代生物标志物可确定 2 型糖尿病和心血管疾病的高危人群。目的:确定胰岛素抵抗的替代生物标志物的频率及其与初级预防非糖尿病高血压受试者 CRC 的相关性:这是一项前瞻性连续门诊病人样本观察登记。TyG指数(TyGi)的计算公式为(空腹甘油三酯[mg/dl]×空腹血浆葡萄糖[mg/dl]/2)的对数(Ln)。根据 TyGi 的四分位数对患者进行分层。评估了TyGi与其他相关变量之间的皮尔逊相关系数:共纳入 46 名患者,平均年龄(55.9±13)岁,男性 231 人(56.9%)。平均 TyGi 为 8.667±0.53。TyGi最高四分位数的患者预期与实际ASCVD风险的中位数差异明显更高(p=0.02),AHA/ACC汇集队列方程>7.5%的频率更高(p2=0.5007;p2=0.2073;p结论:TyGi是胰岛素抵抗的替代生物标志物,根据AHA/ACC联合队列方程,TyGi高的非糖尿病高血压患者10年心血管风险更高。TyGi与胰岛素抵抗的其他生物标志物在统计学上有显著相关性。在临床实践中,TyGi可作为一种可靠的生物标志物来对心血管风险进行分层。
{"title":"Metabolic biomarkers and cardiovascular risk stratification in hypertension","authors":"D. Piskorz,&nbsp;L. Keller,&nbsp;L. Citta,&nbsp;G. Tissera,&nbsp;L. Mata,&nbsp;L. Bongarzoni","doi":"10.1016/j.hipert.2024.06.003","DOIUrl":"10.1016/j.hipert.2024.06.003","url":null,"abstract":"<div><h3>Introduction</h3><p>Cardiovascular risk calculators (CRC) are not locally validated and calibrated. Surrogate biomarkers of insulin resistance had identified subjects at higher risk of type 2 diabetes and cardiovascular disease.</p></div><div><h3>Aim</h3><p>Establish the frequency of surrogate biomarkers of insulin resistance and their correlation with CRC in primary prevention non-diabetic hypertensive subjects.</p></div><div><h3>Methods</h3><p>This is an observational registry with a prospective consecutive outpatient's sample. The TyG index (TyGi) was calculated as logarithm (Ln) of (fasting triglycerides [mg/dl]<!--> <!-->×<!--> <!-->fasting plasma glucose [mg/dl]/2). Patients were stratified according to quartiles of TyGi. Pearson correlation coefficient between TyGi and other relevant variables was evaluated.</p></div><div><h3>Results</h3><p>Four hundred six patients were included with a mean age 55.9<!--> <!-->±<!--> <!-->13 years, 231 p (56.9%) males. The mean TyGi was 8.667<!--> <!-->±<!--> <!-->0.53. Patients in the highest quartiles of TyGi had significantly higher median difference between expected and actual ASCVD risk (<em>p</em> <!-->=<!--> <!-->0.02), higher frequency of AHA/ACC Pooled Cohort Equation &gt;7.5% (<em>p</em> <!-->&lt;<!--> <!-->0.005), and higher levels of metabolic biomarkers such as median triglyceridemia/HDL cholesterol ratio (TG/HDL) (<em>p</em> <!-->&lt;<!--> <!-->0.0005), glycaemia and A1C (<em>p</em> <!-->&lt;<!--> <!-->0.001 and <em>p</em> <!-->=<!--> <!-->0.02, respectively). The correlation between TyGi and TG/HDL was highly significant (<em>r</em> <!-->=<!--> <!-->0.7076; <em>r</em><sup>2</sup> <!-->=<!--> <!-->0.5007; <em>p</em> <!-->&lt;<!--> <!-->0.0001), and intermediate with non-HDL cholesterol (<em>r</em> <!-->=<!--> <!-->0.4553, <em>r</em><sup>2</sup> <!-->=<!--> <!-->0.2073; <em>p</em> <!-->&lt;<!--> <!-->0.0001).</p></div><div><h3>Conclusions</h3><p>Non-diabetic hypertensive patients with high TyGi, a surrogate biomarker of insulin resistance, had a higher 10-year cardiovascular risk by AHA/ACC Pooled Cohort Equation. TyGi is statistically and significantly correlated with other biomarkers of insulin resistance. TyGi could be a reliable biomarker in clinical practice to stratify cardiovascular risk.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.hipert.2024.05.001
{"title":"","authors":"","doi":"10.1016/j.hipert.2024.05.001","DOIUrl":"10.1016/j.hipert.2024.05.001","url":null,"abstract":"","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141950434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HT and uric acid, uric acid and HT: Is hyperuricemia a new vascular risk factor to consider? 高血压与尿酸、尿酸与高血压:高尿酸血症是需要考虑的新血管风险因素吗?
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.hipert.2024.06.001
Mencia Benitez Camps
{"title":"HT and uric acid, uric acid and HT: Is hyperuricemia a new vascular risk factor to consider?","authors":"Mencia Benitez Camps","doi":"10.1016/j.hipert.2024.06.001","DOIUrl":"10.1016/j.hipert.2024.06.001","url":null,"abstract":"","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141793693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Pheochromocytoma as a simulator of cardiac pathology]. [嗜铬细胞瘤作为心脏病理学的模拟器]。
IF 0.6 Q3 Medicine Pub Date : 2024-05-20 DOI: 10.1016/j.hipert.2024.04.006
M J Vallejo Herrera, V Vallejo Herrera, V Márquez Pérez, F Serrano Puche, I Vegas Vegas

Pheochromocytomas are rare neuroendocrine tumors that can present as hypertensive crises or serious cardiac and cerebrovascular complications that endanger the patient's life. Two unusual cases of adrenergic crises induced by pheochromocytoma with cardiovascular manifestations are presented, one with multiple complications/multiorgan failure, fatal outcome and definitive diagnosis in the post mortem autopsy, and another with a satisfactory evolution after diagnosis and appropriate treatment.

嗜铬细胞瘤是一种罕见的神经内分泌肿瘤,可表现为高血压危象或严重的心脑血管并发症,危及患者生命。本文介绍了两例不寻常的嗜铬细胞瘤诱发肾上腺素能危象并伴有心血管表现的病例,其中一例伴有多种并发症/多器官功能衰竭、致命的结果,并在尸检中得到明确诊断;另一例在确诊并接受适当治疗后,病情发展令人满意。
{"title":"[Pheochromocytoma as a simulator of cardiac pathology].","authors":"M J Vallejo Herrera, V Vallejo Herrera, V Márquez Pérez, F Serrano Puche, I Vegas Vegas","doi":"10.1016/j.hipert.2024.04.006","DOIUrl":"https://doi.org/10.1016/j.hipert.2024.04.006","url":null,"abstract":"<p><p>Pheochromocytomas are rare neuroendocrine tumors that can present as hypertensive crises or serious cardiac and cerebrovascular complications that endanger the patient's life. Two unusual cases of adrenergic crises induced by pheochromocytoma with cardiovascular manifestations are presented, one with multiple complications/multiorgan failure, fatal outcome and definitive diagnosis in the post mortem autopsy, and another with a satisfactory evolution after diagnosis and appropriate treatment.</p>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Consequence of hypertensive disorders during pregnancy (THE) on women's cardiovascular health]. [妊娠期高血压疾病(THE)对妇女心血管健康的影响]。
IF 0.6 Q3 Medicine Pub Date : 2024-05-13 DOI: 10.1016/j.hipert.2024.04.005
W G Espeche, P Carrera Ramos, J Minetto, D Gomez, A De Iraola, G R Cerri, M R Salazar

Patients with hypertensive disorders of pregnancy (HDP) are at increased risk of maternal-fetal complications and represent the third leading cause of maternal mortality. To date, it is known that women experiencing this condition during pregnancy have a higher future risk of cardiovascular events (CVD). Our objective was to report the incidence of new-onset hypertension in the postpartum period. We conducted a cohort study in high-risk pregnant patients who underwent ambulatory blood pressure monitoring (ABPM) between weeks 20-30. Patients were categorized as normotensive (NT) or gestational hypertensive (GH), excluding those with chronic hypertension, and were followed until the end of pregnancy with a postpartum assessment after 3months. Patients with HDP (39%) had a higher incidence of preeclampsia and newborns with low birth weight and preterm birth. A total of 177 pregnant women were analyzed for the primary outcome. Among those with GH, 33.3% vs 17.2% of NT (P=.014) reported new-onset hypertension. The odds ratio for developing new-onset hypertension was 2.3 (95%CI: 1.20-4.77), for those with GH. In conclusion, pregnant patients with GH assessed by ABPM between 20-30weeks are at higher risk of developing new-onset hypertension in the postpartum period, emphasizing the need for closer monitoring and control to prevent future cardiovascular complications.

妊娠期高血压疾病(HDP)患者发生母胎并发症的风险增加,是导致孕产妇死亡的第三大原因。迄今为止,人们已经知道,在妊娠期间患有这种疾病的妇女未来发生心血管事件(CVD)的风险较高。我们的目的是报告产后新发高血压的发病率。我们对在怀孕 20-30 周期间接受动态血压监测 (ABPM) 的高危孕妇进行了一项队列研究。患者被分为血压正常(NT)和妊娠高血压(GH)两类,其中不包括慢性高血压患者,随访至妊娠结束,并在产后 3 个月进行评估。妊娠高血压患者(39%)的子痫前期、新生儿低出生体重和早产的发生率较高。共有 177 名孕妇接受了主要结果分析。在患有 GH 的孕妇中,33.3%(P=0.014)与 17.2%(P=0.014)的 NT 孕妇报告了新发高血压。GH患者新发高血压的几率比为2.3(95%CI:1.20-4.77)。总之,在20-30周期间接受ABPM评估的GH孕妇在产后罹患新发高血压的风险较高,这强调了更密切监测和控制以预防未来心血管并发症的必要性。
{"title":"[Consequence of hypertensive disorders during pregnancy (THE) on women's cardiovascular health].","authors":"W G Espeche, P Carrera Ramos, J Minetto, D Gomez, A De Iraola, G R Cerri, M R Salazar","doi":"10.1016/j.hipert.2024.04.005","DOIUrl":"https://doi.org/10.1016/j.hipert.2024.04.005","url":null,"abstract":"<p><p>Patients with hypertensive disorders of pregnancy (HDP) are at increased risk of maternal-fetal complications and represent the third leading cause of maternal mortality. To date, it is known that women experiencing this condition during pregnancy have a higher future risk of cardiovascular events (CVD). Our objective was to report the incidence of new-onset hypertension in the postpartum period. We conducted a cohort study in high-risk pregnant patients who underwent ambulatory blood pressure monitoring (ABPM) between weeks 20-30. Patients were categorized as normotensive (NT) or gestational hypertensive (GH), excluding those with chronic hypertension, and were followed until the end of pregnancy with a postpartum assessment after 3months. Patients with HDP (39%) had a higher incidence of preeclampsia and newborns with low birth weight and preterm birth. A total of 177 pregnant women were analyzed for the primary outcome. Among those with GH, 33.3% vs 17.2% of NT (P=.014) reported new-onset hypertension. The odds ratio for developing new-onset hypertension was 2.3 (95%CI: 1.20-4.77), for those with GH. In conclusion, pregnant patients with GH assessed by ABPM between 20-30weeks are at higher risk of developing new-onset hypertension in the postpartum period, emphasizing the need for closer monitoring and control to prevent future cardiovascular complications.</p>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140923622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is proteinuria an important fact concerning the nephroprotective effect of renin-angiotensin system inhibitors? 蛋白尿是否是肾素-血管紧张素系统抑制剂肾保护作用的一个重要事实?
IF 0.6 Q3 Medicine Pub Date : 2024-04-01 DOI: 10.1016/j.hipert.2024.02.007
J.M. Galceran
{"title":"Is proteinuria an important fact concerning the nephroprotective effect of renin-angiotensin system inhibitors?","authors":"J.M. Galceran","doi":"10.1016/j.hipert.2024.02.007","DOIUrl":"10.1016/j.hipert.2024.02.007","url":null,"abstract":"","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antihipertensivos, presión positiva continua en la vía aérea y apnea obstructiva del sueño 抗高血压药、持续气道正压和阻塞性睡眠呼吸暂停
IF 0.6 Q3 Medicine Pub Date : 2024-04-01 DOI: 10.1016/j.hipert.2024.02.005
{"title":"Antihipertensivos, presión positiva continua en la vía aérea y apnea obstructiva del sueño","authors":"","doi":"10.1016/j.hipert.2024.02.005","DOIUrl":"https://doi.org/10.1016/j.hipert.2024.02.005","url":null,"abstract":"","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140540629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Title Page 标题页
IF 0.6 Q3 Medicine Pub Date : 2024-04-01 DOI: 10.1016/S1889-1837(24)00073-4
{"title":"Title Page","authors":"","doi":"10.1016/S1889-1837(24)00073-4","DOIUrl":"https://doi.org/10.1016/S1889-1837(24)00073-4","url":null,"abstract":"","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140880254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergencia hipertensiva como debut de síndrome de Cushing paraneoplásico [高血压急症是副肿瘤性库欣综合征的首发症状]。
IF 0.6 Q3 Medicine Pub Date : 2024-04-01 DOI: 10.1016/j.hipert.2023.10.003
E. Rubio González, M. de Valdenebro Recio, M.I. Galán Fernández

We present the case of a patient with a history of renal-vascular hypertension treated with stent one year previously, who attended the emergency room due to hypertensive emergency and dyspnea. Once the first suspicion of renal artery restenosis was ruled out with CT angiography, the study was completed, confirming the diagnosis of lung cancer through imaging and pathological anatomy. In the hormonal study, elevation of ACTH, hypercortisolism and analytical data of hyperaldosteronism were detected. With the final diagnosis of Cushing's syndrome secondary to ectopic production of ACTH, medical treatment was started, without being able to receive anything else due to the death of the patient after a few days.

我们介绍的病例是一名一年前曾接受支架治疗的肾血管性高血压患者,因高血压急症和呼吸困难到急诊就诊。在通过 CT 血管造影排除肾动脉再狭窄的初步怀疑后,研究完成,通过影像学和病理解剖确诊为肺癌。在激素检查中,发现了促肾上腺皮质激素升高、皮质醇增多和高醛固酮血症的分析数据。最终诊断为继发于促肾上腺皮质激素异位分泌的库欣综合征,于是开始进行药物治疗,但由于几天后患者死亡,无法接受其他治疗。
{"title":"Emergencia hipertensiva como debut de síndrome de Cushing paraneoplásico","authors":"E. Rubio González,&nbsp;M. de Valdenebro Recio,&nbsp;M.I. Galán Fernández","doi":"10.1016/j.hipert.2023.10.003","DOIUrl":"10.1016/j.hipert.2023.10.003","url":null,"abstract":"<div><p>We present the case of a patient with a history of renal-vascular hypertension treated with stent one year previously, who attended the emergency room due to hypertensive emergency and dyspnea. Once the first suspicion of renal artery restenosis was ruled out with CT angiography, the study was completed, confirming the diagnosis of lung cancer through imaging and pathological anatomy. In the hormonal study, elevation of ACTH, hypercortisolism and analytical data of hyperaldosteronism were detected. With the final diagnosis of Cushing's syndrome secondary to ectopic production of ACTH, medical treatment was started, without being able to receive anything else due to the death of the patient after a few days.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hipertension y Riesgo Vascular
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1